Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download A2780ADR (Ovary, human)
Document related concepts
Transcript
Cat. No. EC93112520 A2780ADR (Ovary, human) Culture Medium : RPMI 1640 + 2 mM Glutamine + 10% Fetal Bovine Serum (FBS); treatment with 10- 7M adriamycin at least once a week. Cell Line description : The adriamycin-resistant cell line A2780ADR has been developed by exposure of the parent A2780 cell line (catalogue no.EC93112519) to adriamycin. A2780ADR is cross-resistant to melphalan and vinblastin. To retain resistance adriamycin has to be added to the media at least once a month. The cells grow as a monolayer and in suspension in spinner cultures and are tumourigenic in immune deficient mice. A2780ADR do not possess the P-170 glycoprotein associated with pleiotropic drug resistance in murine tumors. Together with the cisplatin-resistant variant A2780cis these lines only differ in their exposure to a single drug and should facilitate the search for molecular changes responsible for the expression of pleiotropic drug resistance in human ovarian cancer. DESCRIPTION OF REPOSITORY REFERENCE SEED STOCK Morph ology : Epithelial. Sub Culture Routine : Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 5×1,000 to 2 × 10,000 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO 2; 37℃. Recommendation: culture cells without drug after resuscitation until growth has been fully established. Karyotype : Not specified. Depositor : Dr T H Ward, Cell Culture Unit, Patterson Laboratories, Chrustie Hospital, Manchester Originator : Yes. Country : UK References : Proc Amer Assoc Cancer Res 1984; 25: 336. Seminars in Oncology 1984; 11: 285.
